Greg M Delgoffe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3811908/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment. Immunity, 2009, 30, 832-844.	6.6	1,079
2	The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunology, 2011, 12, 295-303.	7.0	970
3	Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion. Immunity, 2016, 45, 358-373.	6.6	560
4	The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity, 2016, 45, 374-388.	6.6	504
5	Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature, 2021, 591, 645-651.	13.7	492
6	Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis. Nature, 2013, 501, 252-256.	13.7	489
7	Interferon-Î ³ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell, 2017, 169, 1130-1141.e11.	13.5	431
8	The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism. Immunity, 2010, 33, 301-311.	6.6	429
9	Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunology Research, 2017, 5, 9-16.	1.6	381
10	The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology, 2012, 13, 290-299.	7.0	371
11	Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nature Immunology, 2021, 22, 205-215.	7.0	358
12	mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. Journal of Clinical Investigation, 2015, 125, 2090-2108.	3.9	329
13	Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Reports, 2018, 22, 1509-1521.	2.9	322
14	Metabolic barriers to cancer immunotherapy. Nature Reviews Immunology, 2021, 21, 785-797.	10.6	245
15	Anergic T Cells Are Metabolically Anergic. Journal of Immunology, 2009, 183, 6095-6101.	0.4	243
16	Interleukin-35 Limits Anti-Tumor Immunity. Immunity, 2016, 44, 316-329.	6.6	230
17	Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation. Nature Immunology, 2016, 17, 704-711.	7.0	199
18	4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. Journal of Experimental Medicine, 2018, 215, 1091-1100.	4.2	197

GREG M DELGOFFE

#	Article	IF	CITATIONS
19	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature, 2021, 591, 652-658.	13.7	187
20	Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ. Immunity, 2019, 51, 381-397.e6.	6.6	186
21	Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. Nature Immunology, 2020, 21, 331-342.	7.0	172
22	The Receptor SIGIRR Suppresses Th17 Cell Proliferation via Inhibition of the Interleukin-1 Receptor Pathway and mTOR Kinase Activation. Immunity, 2010, 32, 54-66.	6.6	171
23	IL-23 and IL-1Î ² Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation. Cell Reports, 2018, 22, 2642-2653.	2.9	157
24	Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight, 2019, 4, .	2.3	148
25	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation. Journal of Clinical Investigation, 2018, 128, 3926-3940.	3.9	136
26	Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nature Communications, 2017, 8, 14649.	5.8	128
27	mTOR: taking cues from the immune microenvironment. Immunology, 2009, 127, 459-465.	2.0	100
28	Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. Journal of Clinical Investigation, 2018, 128, 4884-4897.	3.9	95
29	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity, 2019, 51, 548-560.e4.	6.6	88
30	Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines, 2016, 4, 46.	2.1	87
31	STAT heterodimers in immunity. Jak-stat, 2013, 2, e23060.	2.2	78
32	Feeding an army: The metabolism of T cells in activation, anergy, and exhaustion. Molecular Immunology, 2015, 68, 492-496.	1.0	65
33	Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations. Cancers, 2020, 12, 3802.	1.7	65
34	IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival. Nature Immunology, 2019, 20, 534-545.	7.0	63
35	Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. , 2021, 9, e002088.		59
36	IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunology Research, 2019, 7, 1258-1266.	1.6	56

GREG M DELGOFFE

#	Article	IF	CITATIONS
37	Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells. Cell Reports, 2019, 27, 129-141.e4.	2.9	55
38	Interpreting mixed signals: the cell's cytokine conundrum. Current Opinion in Immunology, 2011, 23, 632-638.	2.4	51
39	Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clinical Cancer Research, 2018, 24, 2473-2481.	3.2	49
40	Metabolic Consequences of T-cell Costimulation in Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1564-1569.	1.6	48
41	NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer. JCI Insight, 2020, 5, .	2.3	43
42	Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Reports, 2021, 36, 109699.	2.9	37
43	The role of exhaustion in CAR T cell therapy. Cancer Cell, 2021, 39, 885-888.	7.7	35
44	Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions. Journal of Immunology, 2017, 198, 640-644.	0.4	34
45	Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. Oncolmmunology, 2020, 9, 1708064.	2.1	33
46	Tumor-Derived α-Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells. Cancer Immunology Research, 2019, 7, 1001-1012.	1.6	31
47	Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation. Molecular Immunology, 2009, 46, 2694-2698.	1.0	30
48	Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. Annual Review of Medicine, 2022, 73, 251-265.	5.0	30
49	Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. Seminars in Immunology, 2021, 52, 101485.	2.7	24
50	Cutting Edge: Regulatory T Cells Do Not Mediate Suppression via Programmed Cell Death Pathways. Journal of Immunology, 2011, 187, 4416-4420.	0.4	23
51	Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul. Cancer Immunology Research, 2016, 4, 1001-1006.	1.6	22
52	The Lysophosphatidylcholine Transporter MFSD2A Is Essential for CD8+ Memory T Cell Maintenance and Secondary Response to Infection. Journal of Immunology, 2019, 203, 117-126.	0.4	22
53	Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease. Science Translational Medicine, 2020, 12, .	5.8	22
54	Fighting in a wasteland: deleterious metabolites and antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	21

GREG M DELGOFFE

#	Article	IF	CITATIONS
55	Fungal sensing enhances neutrophil metabolic fitness by regulating antifungal Glut1 activity. Cell Host and Microbe, 2022, 30, 530-544.e6.	5.1	21
56	Sugar, fat, and protein: new insights into what T cells crave. Current Opinion in Immunology, 2015, 33, 49-54.	2.4	19
57	mTORC2 Deficiency Alters the Metabolic Profile of Conventional Dendritic Cells. Frontiers in Immunology, 2019, 10, 1451.	2.2	13
58	Identity Crisis: It's Not Just Foxp3 Anymore. Immunity, 2012, 37, 759-761.	6.6	7
59	Exploring Functional In Vivo Consequences of the Selective Genetic Ablation of mTOR Signaling in T Helper Lymphocytes. Methods in Molecular Biology, 2012, 821, 317-327.	0.4	7
60	PP2A's restraint of mTOR is critical for Treg cell activity. Nature Immunology, 2016, 17, 478-479.	7.0	6
61	A Fox of a different color: FoxA1 programs a new regulatory T cell subset. Nature Medicine, 2014, 20, 236-237.	15.2	4
62	VHL Brings Warburg into the Memory Spotlight. Immunity, 2016, 45, 953-955.	6.6	3
63	Editorial: Diverse responses to <scp>SARSâ€CoV</scp> â€2 in the human population. Immunology, 2022, 166, 1-1.	2.0	1
64	Response to Comment on "Cutting Edge: Regulatory T Cells Do Not Mediate Suppression via Programmed Cell Death Pathways― Journal of Immunology, 2012, 188, 5204-5205.	0.4	0
65	Reversing T Cell Dysfunction for Tumor Immunotherapy. , 2016, , 109-128.		0
66	Analyzing Melanoma Cell Oxygen Consumption and Extracellular Acidification Rates Using Seahorse Technology. Methods in Molecular Biology, 2021, 2265, 81-89.	0.4	0
67	Interleukin-35: A Novel Mediator of Peripheral Tolerance. , 2014, , 377-387.		0
68	Metabolic â€~De-Programming' of Neutrophils Protects Against Fatal Bloodstream Fungal Infections in Kidney Disease. SSRN Electronic Journal, 0, , .	0.4	0
69	COVIDâ€19 vaccination and treatment in vulnerable populations. Immunology, 2022, 165, 141-142.	2.0	0
70	Editorial: Perspectives on the landscape of immunology from Nikhil Joshi. Immunology, 2022, 165, 369-370.	2.0	0
71	Niche topics and location, location, location, with Amanda Lund. Immunology, 2022, 166, 153-154.	2.0	0
72	Editorial: Streamlining the process of submissions to <i>Immunology</i> . Immunology, 2022, 166, 267-267.	2.0	0